stockrow
Friday 6 November 2026
Export XRAY’s income statement to Excel — free account
DENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
9.57
0.52
−5.15%
Follow XRAY
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.49 | 0.58 | 0.63 | 0.62 | |
P/FCF ratio |
18.58 | 14.92 | 23.42 | 23.02 | |
P/Operating CF |
55.15 | 21.40 | 57.97 | 22.57 | |
P/B ratio |
1.30 | 1.57 | 1.76 | 1.70 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.99 | 1.06 | 1.12 | 1.08 | |
EV/EBITDA |
8.71 | 9.50 | 11.58 | 8.72 | |
EV/Operating CF |
13.07 | 12.15 | 15.43 | 16.89 | |
EV/FCF |
37.42 | 27.29 | 41.77 | 40.08 | |
Quick Ratio |
0.66 | 0.72 | 0.67 | 0.76 | |
Current Ratio |
1.63 | 1.63 | 1.53 | 1.51 | |
Net Debt/EBITDA |
0.00 | 10.52 | 41.27 | 24.13 | |
Debt/Assets |
38.25% | 38.36% | 38.36% | 37.12% | |
Debt/Equity |
1.47 | 1.48 | 1.52 | 1.50 | |
Asset Turnover |
0.66 | 0.65 | 0.65 | 0.66 | |
Operating CF/Net income |
(16.00) | 2.68 | (4.00) | (0.69) | |
Capex/Depreciation |
— | (0.46) | (0.66) | (0.20) | |
Interest Coverage |
1.48 | 3.73 | (1.46) | (6.32) | |
Research and Development Expense of Revenue |
5.02% | 5.01% | 5.00% | 4.16% | |
Selling, General and Administrative Expense of Revenue |
43.42% | 40.53% | 39.89% | 39.85% | |
Intangible Assets out of Total Assets |
0.38 | 0.39 | 0.40 | 0.39 | |
Share Based Compensation of Revenue |
0.96% | 1.00% | 0.91% | 0.83% | |
Graham Net Nets |
(1.05) | (0.91) | (0.89) | (0.91) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.00%) | (25.92%) | (27.16%) | (26.25%) | |
Free Cash Flow Yield |
5.38% | 6.70% | 4.27% | 4.34% | |
Revenue per Share |
4.20 | 4.50 | 4.40 | 4.82 | |
Operating CF per Share |
0.16 | 0.50 | 0.20 | 0.51 | |
Capex per Share |
0.00 | (0.20) | (0.26) | (0.21) | |
Free Cash Flow per Share |
0.16 | 0.30 | (0.06) | 0.30 | |
Cash per Share |
0.98 | 1.20 | 0.95 | 1.63 | |
Shareholders Equity per Share |
6.80 | 6.77 | 6.60 | 6.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.80 | 6.77 | 6.60 | 6.72 | |
Free Cash Flow |
32.00 | 60.00 | (12.00) | 60.00 | |
Working Capital |
761.00 | 743.00 | 638.00 | 680.00 | |
Capital Expenditures |
— | (39.00) | (52.00) | (41.00) | |
Net Current Asset Value |
(1,858.00) | (1,925.00) | (2,065.00) | (2,066.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.06 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
629.50 | 633.00 | 613.00 | 622.00 | |
Average Payables |
253.00 | 264.00 | 267.50 | 270.50 | |
Average Inventory |
696.50 | 670.00 | 635.50 | 603.00 | |
Average Assets |
5,421.50 | 5,636.50 | 5,639.50 | 5,591.00 | |
Average Common Equity |
1,416.00 | 1,656.00 | 1,664.50 | 1,641.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026